Abstract

Background Spondyloarthritis refers to a group of chronic inflammatory diseases with unknown etiologies that involve particularly sacroiliac joints and spine but may also affect the remaining joints and entheses and exhibit extra-articular involvement in some patients. Oxytocin is a peptide hormone released from hypothalamus and stored in pituitary gland. It has been known for a while that oxytocin has anti-inflammatory effects and can cause a reduction in TNF-alpha levels. Objectives The aim of this study was to investigate the serum levels of oxytocin and its potential association with disease activity, spinal mobility and some other laboratory parameters such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in patients with ankylosing spondylitis (AS) and non-radiographic axial spondylitis (nrAxSpA). Methods Seventy-one patients with nrAxSpA and 38 patients with AS who presented to the Outpatient Clinic of Physical Medicine and Rehabilitation of Dicle University Hospital between March 2017- October 2017 and 67 healthy control subjects were included in this study. All the subjects underwent a thorough physical examination. Disease activity was assessed by Bath Ankylosing Spondylitis Disease Activity Index, and spinal mobility by Bath Ankylosing Spondylitis Metrologic Index. Laboratory examinations included complete blood count, ESR, CRP, and oxytocin tests. Results There was no significant difference in serum levels of oxytocin among the three groups (p= 0.973). However, serum levels of oxytocin correlated negatively with both ESR (r= -0.359, p=0.027) and BASDAI scores (r= -0,448, p=0.005) in patients with AS. On the other hand, serum levels of oxytocin had a negative correlation only with ESR in the patients with nrAxSpA (r= -0.321 p= 0.009). Conclusion ESR is one of the parameters associated with disease activity in patients with inflammatory rheumatoid diseases. Serum levels of oxytocin correlating negatively with both ESR and BASDAI scores in patients with AS and only with ESR in patients with nrAxSpA suggests that low levels of oxytocin may be associated with increased disease activity. This study lays the foundation for further studies that may aim to investigate how addition of oxytocin to the treatment regimen impact on the disease activity in patients with AS who exhibit particularly low levels of oxytocin during active disease period.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.